Related Experiment Video

Updated: May 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

Left Atrial Appendage Closure: Therapy Overview and Future Perspective

George H Nasr1, Parker M Rushworth1, David M Donaldson1

  • 1Division of Cardiology, University of California, Irvine, 101 The City Drive South Suite 407, Orange, CA 92868, USA.

Cardiology Clinics
|June 23, 2024
PubMed

Insights

Left atrial appendage occlusion (LAAO) offers a stroke risk reduction strategy for atrial fibrillation (AF) patients unsuitable for anticoagulation. This review covers LAAO's anatomy, techniques, outcomes, and future potential.

Area of Science:

  • Cardiology
  • Interventional Cardiology

Background:

  • The left atrial appendage (LAA) is a primary source of thromboembolic events in atrial fibrillation (AF).
  • Left atrial appendage occlusion (LAAO) is an alternative to anticoagulation for stroke prevention in AF patients.
  • Patient selection for LAAO is critical, particularly for those with contraindications to anticoagulation.

Purpose of the Study:

  • To provide a comprehensive review of left atrial appendage occlusion (LAAO).
  • To discuss the anatomical considerations, procedural techniques, and clinical outcomes of LAAO.
  • To explore future directions and advancements in LAAO therapy.

Main Methods:

  • Systematic literature review of LAAO procedures and outcomes.
  • Analysis of anatomical variations of the LAA relevant to occlusion.
  • Evaluation of current LAAO device technologies and implantation techniques.

Main Results:

  • LAAO effectively reduces the risk of stroke and systemic embolism in selected AF patients.
  • Various LAAO devices and techniques demonstrate favorable safety and efficacy profiles.
  • Long-term data on LAAO outcomes are still evolving, with ongoing research into optimal patient selection and device innovation.

Conclusions:

  • LAAO is a viable and increasingly utilized therapeutic option for stroke prevention in AF patients.
  • Continued research is essential to refine LAAO techniques, device technology, and long-term outcome prediction.
  • LAAO represents a significant advancement in managing thromboembolic risk in atrial fibrillation.

Keywords:
AnticoagulationAtrial fibrillationCardiac thrombusLeft atrial appendage occlusionStroke preventionSystemic embolization

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.7K

Related Concept Videos

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...